18.99
0.84 (4.63%)
| Previous Close | 18.15 |
| Open | 18.15 |
| Volume | 940,279 |
| Avg. Volume (3M) | 532,098 |
| Market Cap | 842,088,768 |
| Price / Earnings (Forward) | 36.10 |
| Price / Sales | 3.83 |
| Price / Book | 6.92 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 - 5 May 2025 |
| Profit Margin | -5.32% |
| Operating Margin (TTM) | 4.08% |
| Diluted EPS (TTM) | -0.230 |
| Quarterly Revenue Growth (YOY) | 15.10% |
| Total Debt/Equity (MRQ) | 68.41% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | 4.54 M |
| Levered Free Cash Flow (TTM) | 3.93 M |
| Return on Assets (TTM) | -1.03% |
| Return on Equity (TTM) | -9.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | AxoGen, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.00 |
|
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 5.50% |
| % Held by Institutions | 81.91% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Lake Street, 57.98%) | Buy |
| Median | 26.00 (36.91%) | |
| Low | 24.00 (Cantor Fitzgerald, 26.38%) | Buy |
| Average | 26.50 (39.55%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 18.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Lake Street | 17 Mar 2025 | 30.00 (57.98%) | Buy | 18.28 |
| Cantor Fitzgerald | 05 Mar 2025 | 24.00 (26.38%) | Buy | 18.21 |
| Citizens Capital Markets | 05 Mar 2025 | 26.00 (36.91%) | Buy | 18.21 |
| 26 Feb 2025 | 26.00 (36.91%) | Buy | 19.46 | |
| Canaccord Genuity | 26 Feb 2025 | 26.00 (36.91%) | Buy | 19.46 |
| 03 Feb 2025 | 22.00 (15.85%) | Buy | 17.92 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Apr 2025 | Announcement | Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025 |
| 24 Mar 2025 | Announcement | Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 25 Feb 2025 | Announcement | Axogen, Inc. To Host Analyst & Investor Day on March 4th |
| 25 Feb 2025 | Announcement | Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results |
| 11 Feb 2025 | Announcement | Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 |
| 03 Feb 2025 | Announcement | Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |